Advertisement

Meningoccal vaccines

  • R. A. Wall
Part of the Immunology and Medicine book series (IMME, volume 12)

Abstract

The first clinical descriptions of meningococcal disease were published in 18051 and 18062. These highlighted the characteristic rash by which clinical infection can be suspected, and the ability of the organism to kill with dramatic speed, a feature which remains equally relevant today.

Keywords

Outer Membrane Protein Neisseria Gonorrhoeae Meningococcal Disease Neisseria Meningitidis Polysaccharide Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vieusseaux, M. (1805). Memoire sur le maladie qui a regne a Geneve au printemps de 1805. J. Med. Chirurg. Pharmacie, II, 163–5Google Scholar
  2. 2.
    Danielson, L. and Mann, E. (1806). Medical and agricultural register, vol. 1; no. 5; quoted in Rev. Infect. Dis., (1983), 5, 969–72PubMedCrossRefGoogle Scholar
  3. 3.
    Hirsch, A. (1886). Handbook of Geographical and Historical Pathology, Vol. 3, p. 547 (London: New Sydenham Soc.) Pub. New Sydenham Soc. No. 117Google Scholar
  4. 4.
    Weichselbaum, A. (1887). Über die aetiologie der akuten meningitis cerebrospinalis. Fortschr. Med., 5, 573–5Google Scholar
  5. 5.
    Poolman, J. T., Lind, L, Jonsdottir, K., Forholm, L. D., Jones, D. M. and Zanen, H. C. (1986). Meningococcal serotypes and serogroup B disease in North West Europe. Lancet, 2, 555–8PubMedCrossRefGoogle Scholar
  6. 6.
    Gotschlich, E. C. (1984). Meningococcal meningitis. In Germanier, R. (ed.), Bacterial Vaccines, pp. 237–55. (New York and London: Academic Press)Google Scholar
  7. 7.
    Jones, D. M. (1988). Epidemiology of meningococcal infection in England and Wales. J. Med. Microbiol., 26, 165–8PubMedGoogle Scholar
  8. 8.
    Caugant, D. A., Froholm, L. O., Borre, K., Holten, E., Frasch, C. E., Mocca, L. F., Zollinger, W. D. and Selander, R. K. (1986). Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl. Acad. Sci. USA, 83, 4927–31PubMedCrossRefGoogle Scholar
  9. 9.
    Shao-Qing, D., Ren-Bang, Y. and Huan-Chun, Z. (1981). Three new serogroups of Neisseria meningitidis. J. Biol. Stand., 9, 307–15CrossRefGoogle Scholar
  10. 10.
    Wall, R. A., Borriello, S. P., Reid, P., Gupta, R., Evans, R. and Jones, D. M. (1988). Isoenzyme analysis of Neisseria meningitidis by Polyacrylamide gel electrophoresis and its application to epidemiological studies in England. J. Med. Microbiol, 27, xiiiGoogle Scholar
  11. 11.
    Masson, L. and Holbein, B. E. (1985). Influence of environmental conditions on serogroup B Neisseria meningitidis capsular polysaccharide levels. In Schoolnik, G. K. (ed.), The Pathogenic Neisseria, pp. 571–8. (Washington, DC: American Society for Microbiology)Google Scholar
  12. 12.
    Gold, R. and Wyle, F. A. (1970). New classification of Neisseria meningitidis by means of bactericidal reactions. Infect. Immun., 1, 479–84PubMedGoogle Scholar
  13. 13.
    Frasch, C. E. and Chapman, S. S. (1972). Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method. Infect. Immun., 5, 98–102PubMedGoogle Scholar
  14. 14.
    Frasch, C. E. and Chapman, S. S. (1972). Classification of Neisseria meningitidis group B into distinct serotypes. II. Extraction of type specific antigens for serotyping by precipitin techniques. Infect. Immun., 6, 127–33PubMedGoogle Scholar
  15. 15.
    Zollinger, W. D., Kasper, D. L., Veltri, B. J. and Artenstein, M. S. (1972). Isolation and characterisation of native cell wall complex from Neisseria meningitidis. Infect. Immun., 6, 835–51PubMedGoogle Scholar
  16. 16.
    Poolman, J. T., Hopman, C. T. P. and Zanen, H. C. (1980). Immunochemical characterisation of Neisseria meningitidis serotype antigens by immunodiffusion and SDS-polyacrylamide gel electrophoresis immunoperoxidase techniques and the distribution of serotypes among cases and carriers. J. Gen. Microbiol., 116, 465–73PubMedGoogle Scholar
  17. 17.
    Zollinger, W. D. and Mandrell, R. E. (1977). Outer membrane protein and lipopolysaccharide serotyping of Neisseria meningitidis by inhibition of a solid phase radioimmunoassay. Infect. Immun. 18, 424–33PubMedGoogle Scholar
  18. 18.
    Frasch, C. E., McNelis, R. M. and Gotschlich, E. C. (1976). Strain specific variation in the protein and lipopolysaccharide composition of the group B meningococcal outer membrane. J. Bacteriol., 127, 973–81PubMedGoogle Scholar
  19. 19.
    Tsai, C. M., Frasch, C. E. and Mocca, L. F. (1981). Five structural classes of major outer membrane proteins in Neisseria meningitidis. J. Bacteriol., 146, 69–78PubMedGoogle Scholar
  20. 20.
    Frasch, C. E., Zollinger, W. D. and Poolman, J. T. (1985). Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis., 7, 504–10PubMedCrossRefGoogle Scholar
  21. 21.
    Lynch, E. C., Blake, M. S., Gotschlich, E. C. and Mawo, A. (1984). Studies on porins spontaneously transferred from whole cells and reconstituted from purified proteins of Neisseria gonorrhoeae and Neisseria meningitidis. Biophys. J., 45, 104–107PubMedCrossRefGoogle Scholar
  22. 22.
    Frasch, C. E. and Mocca, L. F. (1982). Strains of Neisseria meningitidis isolated from patients and their close contacts. Infect. Immun., 37, 155–9PubMedGoogle Scholar
  23. 23.
    Abdillahi, H. and Poolman, J. T. (1988). Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microbiol. Pathogen., 4, 27–32CrossRefGoogle Scholar
  24. 24.
    Crowe, B. A., Abdillahi, H., Poolman, J. T. and Achtman, M. (1988). Correlation of serological typing and cloning typing methods for Neisseria meningitidis sero-group A. J. Med. Microbiol., 26, 183–4PubMedGoogle Scholar
  25. 25.
    Poolman, J. T., De Marie, S. and Zanen, H. C. (1980). Variability of low molecular weight, heat modification outer membrane proteins of Neisseria meningitidis. Infect. Immun., 30, 642–8PubMedGoogle Scholar
  26. 26.
    Achtman, M., Crowe, B. A., Olyhoek, A., Strittmater, W. and Morlli, G. (1988). Recent results on epidemic meningococcal meningitidis. J. Med. Microbiol., 26, 172–7PubMedGoogle Scholar
  27. 27.
    Wall, R. A., unpublishedGoogle Scholar
  28. 28.
    Poolman, J. T., Hopman, C. T. P. and Zanen, H. C. (1982). Problems in the definition of meningococcal serotypes. FEMS Microbiol. Lett., 13, 339–48CrossRefGoogle Scholar
  29. 29.
    Tinsley, C. R. and Heckels, J. E. (1986). Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection. J. Gen. Microbiol., 132, 2483–90PubMedGoogle Scholar
  30. 30.
    Poolman, J. T., Hopman, C. T. P. and Zanen, H. C. (1985). Colony variants of Neisseria meningitidis strain 2996 (B:2b:P1.2): Influence of class 5 outer membrane proteins and lipopolysaccharides. J. Med. Microbiol., 19, 203–9PubMedCrossRefGoogle Scholar
  31. 31.
    Kawula, T. H, Aho, E. L., Barritt, D. S., Klapper, D. G. and Cannon, J. G. (1988). Reversible phase variation of expression of Neisseria meningitidis class 5 outer membrane proteins and their relationship to gonococcal proteins. II. Infect. Immun., 56, 380–6PubMedGoogle Scholar
  32. 32.
    Lambden, P. R., Heckels, J. E., James, L. T. and Watt, P. J. (1979). Variations in surface protein composition associated with virulence properties in opacity types of Neisseria gonorrhoeae. J. Gen. Microbiol., 114, 305–12PubMedGoogle Scholar
  33. 33.
    Virji, M. and Heckels, J. E. (1986). The effect of protein II and pili on the interaction of Neisseria gonorrhoeae with human polymorphonuclear leucocytes. J. Gen. Microbiol., 132, 503–12PubMedGoogle Scholar
  34. 34.
    Achtman, M., Neibert, M., Crowe, B. A., Strittmatter, W., Kusecek, B., Weyse, E., Walsh, M. J., Slawig, B., Morelli, G., Moll, A. and Blake, M. (1988). Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A. J. Exp. Med., 168, 507–25PubMedCrossRefGoogle Scholar
  35. 35.
    Gotschlich, E. C. (1988). Molecular studies of Neisserial outer membrane proteins. Abstracts of the Sixth International Pathogenic Neisseria Conference, Atlanta Georgia, p. 152Google Scholar
  36. 36.
    Hitchcock, P. J., Leive, L., Makela, P. H., Rietschel, E. T., Strittmater, W. and Morrison, D. C. (1986). Lipopolysaccharide nomenclature — past, present and future. J. Bacteriol., 166, 699–705PubMedGoogle Scholar
  37. 37.
    Griffiss, J. M., Schneider, H., Mandrell, R. E., Yamasaki, R., Jarvis, G. A., Kim, J. J., Gibson, B. W., Hamadeh, R. and Apicella, M. A. (1988). Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane. Rev. Infect. Dis., 10, S287–S295PubMedGoogle Scholar
  38. 38.
    Griffiss, J. M., O’Brien, J. P., Jamasaki, R., Williams, G. D., Rice, P. A. and Schneider, H. (1987). Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infect. Immun., 55, 1792–1800PubMedGoogle Scholar
  39. 39.
    Mandrell, R., Schneider, H., Apicella, M., Zollinger, W., Rice, P. A. and Griffiss, J. M. (1986). Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharides. Infect. Immun., 54, 63–69PubMedGoogle Scholar
  40. 40.
    Poolman, J. T., Wientjes, F. B., Hopman, C. T. P. and Zanen, H. C. (1985). Influence of the length of lipopolysaccharide molecules on the surface exposure of class 1 and class 2 outer membrane proteins of Neisseria meningitidis. In Schoolnik, G. K., Brooks, G. F., Falkow, S., Frasch, C. E., Knapp, J. S., McCutchan, J. A. and Morse, S. A. (eds.), The Pathogenic Neisseria: Proceedings of the Fourth International Symposium, pp. 562–70. (Washington, DC: American Society of Microbiology)Google Scholar
  41. 41.
    Morse, S. A., Mintz, C. M., Sarafian, S. K., Bartenstein, L., Bertram, M. and Apicella, M. A. (1983). Effect of dilution rate on lipopolysaccharide and serum resistance to Neisseria gonorrhoeae grown in continuous culture. Infect. Immun., 41, 74–82PubMedGoogle Scholar
  42. 42.
    Apicella, M. A., Shero, M., Jarvis, G. A., Griffiss, J. M., Mandrell, R. E. and Schneider, H. (1987). Phenotypic variation in epitope expression of Neisseria gonorrhoeae lipooligosaccharide. Infect. Immun., 55, 1755–61PubMedGoogle Scholar
  43. 43.
    Schneider, H., Hammack, C. A., Apicella, M. A. and Griffiss, J. M. (1988). Instability of Expression of lipooligosaccharides and their epitopes in Neisseria gonorrhoeae. Infect. Immun., 56, 942–6PubMedGoogle Scholar
  44. 44.
    Schneider, H., Griffiss, J. M., Mandrell, R. E. and Jarvis, G. A. (1985). Elaboration of a 3.6 kilodalton lipooligosaccharide, antibody against which is absent from human sera, is associated with serum resistance of Neisseria gonorrhoeae. Infect. Immun., 50, 672–7PubMedGoogle Scholar
  45. 45.
    Devoe, I. W. and Gilchrist, J. E. (1978). Piliation and colonial morphology among laboratory strains of meningococci. J. Clin. Microbiol., 7, 379–84PubMedGoogle Scholar
  46. 46.
    Stephens, D. S., Edwards, K. M., Morris, F. and McGee, Z. A. (1982). Pili and outer membrane appendages on Neisseria meningitidis in the cerebrospinal fluid of an infant. J. Infect. Dis., 146, 568PubMedCrossRefGoogle Scholar
  47. 47.
    Stephens, D. S. and McGee, Z. A. (1981). Attachment of Neisseria meningitidis to human mucosal surfaces: influence of pili and type of receptor cell. J. Infect. Dis., 143, 525–32PubMedCrossRefGoogle Scholar
  48. 48.
    Virji, M. and Heckels, J. E. (1983). Antigenic cross reactivity of Neisseria pili: investigations with type and species specific monoclonal antibodies. J. Gen. Microbiol., 129, 2761–8PubMedGoogle Scholar
  49. 49.
    Stephens, D. S., Whitney, A. M., Rothbard, J. and Schoolnik, G. K. (1985). Pili of Neisseria meningitidis. Analysis of structure and investigation of structural and antigenic relationships to gonococcal pili. J. Exp. Med., 161, 1539–53PubMedCrossRefGoogle Scholar
  50. 50.
    Diaz, J. L., Virji, M. and Heckels, J. E. (1984). Structural and antigenic differences between two types of meningococcal pili. FEMS Microbiol. Lett., 21, 181–4CrossRefGoogle Scholar
  51. 51.
    Goldschneider, I., Gotschlich, E. C. and Artenstein, M. S. (1969). Human immunity to the meningococcus-I. The role of humoral antibodies. J. Exp. Med., 129, 1307–26PubMedCrossRefGoogle Scholar
  52. 52.
    Sippel, J. E. (1981). Meningococci. C.R.C. Critical Reviews in Microbiology, 1, 267–302CrossRefGoogle Scholar
  53. 53.
    Kayhty, H., Jousimies-Somer, H., Peltola, H. and Makela, P. H. (1981). Antibody response to capsular polysaccharides of Groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J. Infect. Dis., 143, 32–41PubMedCrossRefGoogle Scholar
  54. 54.
    Griffiss, J. M., Brandt, B. L., Broud, D. D., Goroff, D. K. and Baker, C. J. (1984). Immune response to infants and children to disseminated infections with Neisseria meningitidis. J. Infect. Dis., 150, 71–9PubMedCrossRefGoogle Scholar
  55. 55.
    Frasch, C. E. (1983). Immunisation against Neisseria meningitidis. In Easman, C. (ed.), Medical Microbiology, Vol. 2: Immunisation Against Bacterial Disease, pp. 115–44. (London and New York: Academic Press)Google Scholar
  56. 56.
    Goldschneider, I., Gotschlich, E. C. and Artenstein, M. S. (1969). Human immunity to the meningococcus-II. Development of natural immunity. J. Exp. Med., 129, 1327–48PubMedCrossRefGoogle Scholar
  57. 57.
    Glode, M. P., Robbins, J. B., Liu, T. Y., Gotschlich, E. C., Orskov, I. and Orskov, F. (1977). Cross antigenicity and immunogenicity between capsular polysaccharides of Group C Neisseria meningitidis and of Escherichia coli K92. J. Infect. Dis., 135, 94–102PubMedCrossRefGoogle Scholar
  58. 58.
    Gold, R. and Lepow, M. (1976). Present status of polysaccharide vaccines in the prevention of meningococcal disease. Adv. Paediatr., 23, 71–93Google Scholar
  59. 59.
    Artenstein, M. S., Brandt, B. L., Tramont, E. C., Branche, W. C., Fleet, H. D. and Cohen, R. L. (1971). Serologic studies of meningococcal infection and polysaccharide vaccination. J. Infect. Dis., 124, 277–88PubMedCrossRefGoogle Scholar
  60. 60.
    Leinonen, M. and Frasch, C. E. (1982). Class-specific antibody response to Group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay. Infect. Immun., 38, 1203–7PubMedGoogle Scholar
  61. 61.
    Kasper, D. L., Windelhake, J. L, Brandt, B. L. and Artenstein, M. S. (1973). Antigenic specificity to bactericidal antibodies in antisera to Neisseria meningitidis. J. Infect. Dis., 127, 378–87PubMedCrossRefGoogle Scholar
  62. 62.
    Holten, E., Vaage, L. and Lyssum, K. (1970). Bactericidal activity in sera from carriers of sulphonamide resistant meningococci. Scand. J. Infect. Dis., 2., 201–4Google Scholar
  63. 63.
    Zollinger, W. D. and Mandrell, R. E. (1983). Importance of complement source in bactericidal antibody and murine monoclonal antibody to meningococci. Infect. Immun., 40, 257–64PubMedGoogle Scholar
  64. 64.
    Zollinger, W. D., Pennington, C. L. and Artenstein, M. S. (1974). Human antibody response to three meningococcal outer membrane antigens: Comparison by specific hemagglutination assays. Infect. Immun., 10, 975–84PubMedGoogle Scholar
  65. 65.
    Frasch, C. E. (1977). Role of protein serotype antigens in protection against disease due to Neisseria meningitidis. J. Infect. Dis., 136, S84–S90PubMedCrossRefGoogle Scholar
  66. 66.
    Jones, D. M. and Eldridge, J. (1979). Development of antibodies to meningococcal protein and lipopolysaccharide serotype antigens in healthy carriers. J. Med. Microbiol., 12, 107–11PubMedCrossRefGoogle Scholar
  67. 67.
    Poolman, J. T., Hopman, C. T. P. and Zanen, H. C. (1983). Immunogenicity of meningococcal antigens as detected in patient sera. Infect. Immun., 40, 398–406PubMedGoogle Scholar
  68. 68.
    Zollinger, W. D. and Mandrell, R. E. (1983). Studies of the human antibody response to specific meningococcal outer membrane proteins of serotype 2 and 15. Med. Trop., 43, 143–7Google Scholar
  69. 69.
    Bundell, K. R., Fox, A. J., Guiver, M., Jones, D. M. and Poolman, J. T. (1987). The development of an inhibition enzyme-linked immunosorbent assay to detect total antibody to the P1.16 subtype antigen of Neisseria meningitidis in human sera. Serodiagn. Immunother., 1, 353–61CrossRefGoogle Scholar
  70. 70.
    Jones, D. M, Fox, A. J, Bundell, K. and Cartwright, K. A. V. (1988). The detection of antibody specific for Neisseria meningitidis class 3 type 15 and class 1 type 16 outer membrane protein antigens in human sera. In Abstracts of the Sixth Pathogenic Neisseria Conference, p. 125Google Scholar
  71. 71.
    Harthug, S., Rosenqvist, E., Hoiby, E. A., Gedde-Dahl, T. W. and Froholm, L. O. (1986). Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen. J. Clin. Microbiol., 24, 947–53PubMedGoogle Scholar
  72. 72.
    Rosenqvist, E., Harthug, S., Froholm, L. O., Hoiby, E. A., Bovre, K. and Zollinger, W. D. (1988). Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J. Clin. Microbiol., 26, 1543–8PubMedGoogle Scholar
  73. 73.
    Sugasawara, R. J. (1985). Recognition of serogroup A Neisseria meningitidis serotype antigens by human antisera. Infect. Immun., 48, 23–8PubMedGoogle Scholar
  74. 74.
    Black, J. R., Dyer, D. W., Thompson, M. K. and Sparling, P. F. (1986). Human immune response to iron-repressible outer membrane proteins of Neisseria meningititis. Infect. Immun., 54, 710–13PubMedGoogle Scholar
  75. 75.
    Griffiss, J. M. and Kim, J. J. (1988). Antigenic specificity of natural bactericidal activity for serogroup B and C strains of Neisseria meningitidis in human sera. In Poolman, J. T. et al (eds), Gonococci and Meningococci, pp. 523–7. (Dordrecht: Kluwer)Google Scholar
  76. 76.
    Gold, R., Goldschneider, I., Lepow, M. L., Draper, T. F. and Randolph, M. (1978). Carriage of Neisseria meningitidis and Neisseria lactamicus in infants and children. J. Infect. Dis., 137, 112–21PubMedCrossRefGoogle Scholar
  77. 77.
    Kim, J. J., Mandrell, R. E., Zhen, H. U., Poolman, J. T. and Griffiss, J. M. (1988). Electromorphic characterisation of the lipooligosaccharides of Group A Neisseria meningitidis. In Poolman, J. T. et al. (eds.), Gonococci and Meningococci, pp. 563–7. (Dordrecht: Kluwer)Google Scholar
  78. 78.
    Thomas, L., Smith, H. W. and Dingle, J. H. (1943). Investigations of meningococcal infection. II. Immunological aspects. J. Clin. Invest., 22, 361–73PubMedCrossRefGoogle Scholar
  79. 79.
    Griffiss, J. M. (1975). Bactericidal activity of meningococcal antisera: blocking by IgA of lytic antibody in human convalescent sera. J. Immunol., 114, 1779–84PubMedGoogle Scholar
  80. 80.
    Griffiss, J. M. and Bertram, M. A. (1977). Immunoepidemiology of meningococcal disease in military recruits—II. Blocking of serum bactericidal activity by circulating IgA early in the course of invasive disease. J. Infect. Dis., 136, 733–9PubMedCrossRefGoogle Scholar
  81. 81.
    Griffiss, J. M. and Goroff, D. K. (1983). IgA blocks IgM and IgG initiated immune lysis by separate molecular mechanisms. J. Immunol., 130, 2882–5PubMedGoogle Scholar
  82. 82.
    Griffiss, J. M. (1982). Epidemic meningococcal disease: Synthesis of a hypothetical immunoepidemiologic model. Rev. Infect. Dis., 4, 159–72PubMedCrossRefGoogle Scholar
  83. 83.
    Rice, P. A, Vayo, H. E., Tarn, M. R. and Blake, M. S. (1986). Immunoglobin G antibodies directed against PIII block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J. Exp. Med., 164, 1745–48CrossRefGoogle Scholar
  84. 84.
    Heckels, J. E. and Virji, M. (1988). Immunobiology of gonococcal outer membrane proteins. In Abstracts of Sixth Pathogenic Neisseria Conference, p. 162.Google Scholar
  85. 85.
    Lim, D., Gewurz, A., Lint, T. F., Cihaze, M., Sepheri, B. and Gewurz, H. (1976). Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J. Pediatr., 89, 42–7PubMedCrossRefGoogle Scholar
  86. 86.
    Lee, T. J., Utsinger, P. D., Snyderman, R., Yount, W. J. and Sparling, P. F. (1978). Familial deficiency of the seventh component of complement associated with recurrent bacteraemic infections due to Neisseria. J. Infect. Dis., 138, 359–68PubMedCrossRefGoogle Scholar
  87. 87.
    Petersen, B. H., Graham, J. A. and Brooks, G. F. (1976). Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoea bactericidal activity. J. Clin. Invest., 57, 283–90PubMedCrossRefGoogle Scholar
  88. 88.
    Haeney, M. R., Ball, A. P. and Thompson, R. A. (1980). Recurrent bacterial meningitis due to genetic deficiencies of the outer membrane antigen. J. Clin. Microbiol., 24, 947–53Google Scholar
  89. 89.
    Leddy, J. P., Frank, M. M., Gaither, T., Baum, J. and Klemperer, M. R. (1974). Hereditary deficiency of the sixth component of complement in man. J. Clin. Invest., 53, 544PubMedCrossRefGoogle Scholar
  90. 90.
    Ross, S. C. and Densen, P. (1984). Complement deficiency states and infection. Medicine (Baltimore), 5, 243–73Google Scholar
  91. 91.
    Nicholson, A. and Lepow, I. (1979). Host defence against Neisseria meningitidis requires a complement dependent bactericidal activity. Science, 205, 298–9PubMedCrossRefGoogle Scholar
  92. 92.
    Lee, T. J., Snyderman, R., Patterson, J., Rauchbach, A. S., Folds, J. D. and Yount, W. J. (1979). Neisseria meningitidis bacteraemia in association with deficiency of the sixth component of complement. Infect. Immun., 24, 656–60PubMedGoogle Scholar
  93. 93.
    Ross, S. C., Rosenthal, P. J., Berberich, H. M. and Densen, P. (1987). Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis., 155, 1266–75PubMedCrossRefGoogle Scholar
  94. 94.
    Hassig, A., Borel, J. R., Amman, P., Thoni, M. and Butler, R. (1964). Essentielle hypokomplementamie. Pathol. Microbiol., 27, 542–7Google Scholar
  95. 95.
    Beatty, D. W., Ryder, C. R. and Heese, H. de V. (1986). Complement abnormalities during an epidemic of Group B meningococcal infection in children. Clin. Exp. Immunol., 64, 465–70PubMedGoogle Scholar
  96. 96.
    Ellison, R. T., Kohler, P. F., Curd, J. G, Judson, F. J. and Relier, L. B. (1983). Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. N. Engl. J. Med., 308, 913PubMedCrossRefGoogle Scholar
  97. 97.
    Grace, H. J., Brereton-Stiles, G. G., Vos, G. H. and Schonland, M. (1976). A family with partial and total deficiency of complement C3. S. Afr. Med. J., 50, 139PubMedGoogle Scholar
  98. 98.
    Thompson, R. A., Yap, P. L., Brettle, R. B., Dunmow, R. E. and Chapel, H. (1983). Meningococcal meningitidis associated with persistent hypocomplementemia due to circulating C3 nephritic factor. Clin. Exp. Immunol., 52, 153–6PubMedGoogle Scholar
  99. 99.
    Thompson, R. A. and Lachmann, P. J. (1977). A second case of human C3b inhibitor (KAF) deficiency. Clin. Exp. Immunol., 27, 23–9PubMedGoogle Scholar
  100. 100.
    Sjoholm, A. G., Braconier, J. H. and Soderstrom, C. (1982). Properdin deficiency in a family with fulminant meningococcal infection. Clin. Exp. Immunol., 50, 291–7PubMedGoogle Scholar
  101. 101.
    Neilsen, H. E. and Koch, C. (1987). Congenital properdin deficiency and meningococcal infection. Clin. Immunol. Immunopathol., 44, 134–9CrossRefGoogle Scholar
  102. 102.
    Densen, P., Weiler, J. M., Griffiss, J. M. and Hoffman, L. G. (1987). Familial properdin deficiency and fatal meningococcaemia. N. Engl. J. Med., 36, 922–6CrossRefGoogle Scholar
  103. 103.
    Kabat, E. A., Kaiser, H. and Silovski, H. (1945). Preparation of the type specific polysaccharide of the type 1 meningococcus and a study of its effectiveness as an antigen in human beings. J. Exp. Med., 80, 299–307CrossRefGoogle Scholar
  104. 104.
    Gotschlich, E. C, Goldschneider, I. and Artenstein, M. S. (1969). Human immunity to the meningococcus-IV. Immunogenicity of Group A and Group C meningococcal polysaccharides in human volunteers. J. Exp. Med., 129, 1367–84PubMedCrossRefGoogle Scholar
  105. 105.
    Brandt, B. L., Wyle, F. A. and Artenstein, M. S. (1972). A radioactive antigen-binding assay for Neisseria meningitidis polysaccharide antibody. J. Immunol., 108, 913–20PubMedGoogle Scholar
  106. 106.
    Kayhty, H., Karanko, V., Peltola, H., Sarna, S. and Makela, P. H. (1980). Serum antibodies to capsular polysaccharide vaccine of Group A Neisseria meningitidis followed for three years in infants and children. J. Infect. Dis., 142, 861–8PubMedCrossRefGoogle Scholar
  107. 107.
    Gold, R., Lepow, M. L., Goldschneider, I, Draper, T. L. and Gotschlich, E. C. (1975). Clinical evaluation of Group A and C meningococcal polysaccharide vaccines in infants. J. Clin. Invest., 56, 1536–47PubMedCrossRefGoogle Scholar
  108. 108.
    Beuvery, E. C., Leussink, A. B., Van Delft, R. W., Tiesjema, R. H. and Nagel, J. (1982). Immunoglobulin M and G antibody responses and persistence of these antibodies in adults after vaccination with a combined meningococcal group A and group C polysaccharide vaccine. Infect. Immun., 37, 579–85PubMedGoogle Scholar
  109. 109.
    Greenwood, B. M., Whittle, H. C. and Bradley, A. K. (1980). The duration of the antibody response to meningococcal vaccination in an African village. Trans. Roy. Soc. Trop. Med. Hyg., 74, 756–60PubMedCrossRefGoogle Scholar
  110. 110.
    Brandt, B. L. and Artenstein, M. S. (1975). Duration of antibody responses after vaccination with Group C Neisseria meningitidis polysaccharide. J. Infect. Dis., 131 (Suppl.), S69–S72PubMedCrossRefGoogle Scholar
  111. 111.
    Sanborn, W. R., Benck, Z., Cvjetanovk, B., Gotschlich, E. C., Pollock, T. M. and Sippel, J. E. (1972). Trial of serogroup A meningococcus polysaccharide vaccine in Nigeria. Prog. Immunobiol. Stand., 5, 497–505PubMedGoogle Scholar
  112. 112.
    Wahdan, M. H., Rizk, F., El-Akkad, A. M., El Ghoroury, A. A., Hablas, R., Girgis, N. I., Amer, A., Boctar, W, Sippel, J. E, Gotschlich, E. C., Triau, R., Sanborn, W. R. and Cvjetanovic, B. (1973). A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. WHO., 48, 667–73PubMedGoogle Scholar
  113. 113.
    Erwa, H. H., Haseeb, M. A., Idris, A. A., Lapeyssonnie, L., Sanborn, W. R. and Sippel, J. E. (1973). A serogroup A meningococcal polysaccharide vaccine. Studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull. WHO., 49, 301–5PubMedGoogle Scholar
  114. 114.
    Peltola, H., Makela, P. H., Kayhty, H., Jousimies, H., Herva, E., Hallstrom, K., Sivonen, A., Renkonen, O. V., Pettay, O., Karanko, V., Ahvonen, P. and Sarna, S. (1977). Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med., 297, 686–91PubMedCrossRefGoogle Scholar
  115. 115.
    Makela, P. H., Kayhty, H., Weckstrom, P., Sivonen, A. and Renkonen, O. V. (1975). Effect of Group A meningococcal vaccine in army recruits in Finland. Lancet, Vol. 8, 883–6CrossRefGoogle Scholar
  116. 116.
    Reingold, A. L., Hightower, A. W., Bolan, G. A., Jones, E. E., Tiendrebeogo, H., Broome, C. V., Ajello, G. W., Adamsbaum, C., Phillips, C. and Yada, A. (1985). Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet, Vol. 20, 114–8CrossRefGoogle Scholar
  117. 117.
    Hu, Z., Rou, Y. L., Chen, C., Chen, R. S., Wu, Q. K., Zhang, V. Y., Dong, C. M., Liu, B. K., Chang, P. Y., Yang, T. Y., Wei, R. T. and Chen, C. Z. (1988). An epidemiological and serological study on duration of protection after meningococcal Group A polysaccharide vaccination. In Poolman, J. T. (ed.), Gonococci and Meningococci, pp. 199–207. (Dordrecht: Kluwer)Google Scholar
  118. 118.
    Greenwood, B. M, Smith, A. W., Hassan-King, M, Bijlmer, H. A., Shenton, F. C., Hughes, A. S. B., Nunn, P. P., Jack, A. D. and Gowers, P. R. S. (1986). The efficacy of meningopolysaccharide vaccine in preventing group A meningococcal disease in The Gambia West Africa. Trans. Roy. Soc. Trop. Med. Hyg., 80, 1006–7PubMedCrossRefGoogle Scholar
  119. 119.
    Wahden, M. H., Sallam, S. A., Hassan, M. N., Gawad, A. A, Rakha, A. S., Sippel, J. E., Hablas, R, Sanborn, W. R., Kassem, N. M., Riad, S. M. and Cvjetanovic, B. (1977). A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull. WHO., 55, 645–51Google Scholar
  120. 120.
    Greenwood, B. M., Hassan-King, M. and Whittle, H. C. (1978). Prevention of secondary cases in household contacts by vaccination. Br. Med. J., 1, 1317–19PubMedCrossRefGoogle Scholar
  121. 121.
    Blakebrough, I. S., Greenwood, B. M., Whittle, H. C., Bradley, A. K. and Gilles, H. M. (1983). Failure of vaccination to stop transmission of meningococci in Nigerian schoolboys. Ann. Trop. Med. Parasitol., 11, 175–8Google Scholar
  122. 122.
    Hassan-King, M. K. A., Wall, R. A. and Greenwood, B. M. (1988). Meningococcal carriage, meningococcal disease and vaccination. J. Infect., 16, 55–9PubMedCrossRefGoogle Scholar
  123. 123.
    Monto, A. S., Brandt, B. L. and Artenstein, M. S. (1973). Response of children to Neisseria meningitidis polysaccharide vaccines. J. Infect. Dis., 127, 394–400PubMedCrossRefGoogle Scholar
  124. 124.
    Gotschlich, E. C., Rey, M., Triau, R. and Sparks, K. J. (1972). Quantitative determination of the human immune response to immunization with meningococcal vaccines. J. Clin. Invest., 51, 89–96PubMedCrossRefGoogle Scholar
  125. 125.
    Artenstein, M. S. and Brandt, B. L. (1975). Immunological hyporesponsiveness in man to Group C meningococcal polysaccharide. J. Immunol., 115, 5–7PubMedGoogle Scholar
  126. 126.
    Tauney, A. de E., Galvao, P. A., de Morais, J. S., Gotschlich, E. C. and Feldman, R. A. (1974). Disease prevention by meningococcal serogroup C polysaccharide vaccine in preschool children. Pediatric Res., 8, 429CrossRefGoogle Scholar
  127. 127.
    Lepow, M. L., Goldschneider, I., Gold, R., Randolph, M. and Gotschlich, E. C. (1977). Persistence of antibody following immunisation of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics, 60, 673–80PubMedGoogle Scholar
  128. 128.
    Gold, R., Lepow, M. L., Goldschneider, I., Draper, T. F. and Gotschlich, E. C. (1979). Kinetics of antibody production to Group A and Group C meningococcal polysaccharide vaccines administered during the first six years of life; prospects for routine immunization of infants and children. J. Infect. Dis., 140, 690–7PubMedCrossRefGoogle Scholar
  129. 129.
    Gold, R. and Artenstein, M. S. (1971). Meningococcal infections. 2. Field trial of Group C meningococcal polysaccharide vaccine in 1969–70. Bull. WHO., 45, 279–82PubMedGoogle Scholar
  130. 130.
    Gotschlich, E. C., Goldschneider, I. and Artenstein, M. S. (1969). Human immunity to the meningococcus-V. The effect of immunization with meningococcal Group C polysaccharide on the carrier state. J. Exp. Med., 129, 1385–95PubMedCrossRefGoogle Scholar
  131. 131.
    Artenstein, M. S., Gold, R., Zimmerly, J. G., Wyle, F. A., Schneider, H. and Harkins, C. (1970). Prevention of meningococcal disease by Group C polysaccharide vaccine. N. Engl. J. Med., 282, 417PubMedCrossRefGoogle Scholar
  132. 132.
    Devine, L. F., Pierce, W. E., Floyd, T. M., Rhode, S. L., Edwards, E. A., Siess, E. E. and Peckinpaugh, R. O. (1970). Evaluation of Group C vaccine in marine recruits, San Diego, California. Am. J. Epidemiol., 92, 25–32PubMedGoogle Scholar
  133. 133.
    Galaid, E. I., Cherubin, C. E., Marr, J. S., Schaefler, S., Barone, J. and Lee, W. (1980). Meningococcal disease in New York City, 1973–1978. Recognition of groups Y and W135 as frequent pathogens. J. Am. Med. Assoc., 244, 2161–11CrossRefGoogle Scholar
  134. 134.
    Griffiss, J. M., Brandt, B. L., Altieri, P. L., Pier, G. B. and Berman, S. L. (1981). Safety and immunogenicity of group Y and Group W135 meningococcal capsular polysaccharide vaccines in adults. Infect. Immun., 34, 725–32PubMedGoogle Scholar
  135. 135.
    Griffiss, J. M., Apicella, M. A., Greenwood, B. and Makela, P. H. (1987). Vaccines against encapsulated bacteria: a global agenda. Rev. Infect. Dis., 9, 176–88PubMedCrossRefGoogle Scholar
  136. 136.
    Whittle, H. C., Oduloju, A., Evans-Jones, G. and Greenwood, B. M. (1976). Evidence for a familial immune defect in meningococcal meningitis. Br. Med. J., 1, 1247–50PubMedCrossRefGoogle Scholar
  137. 137.
    Pandey, J. P., Fudenberg, H. H., Virella, G., Kyong, C. U., Loadholt, C. B., Galbraith, R. M., Gotschlich, E. C. and Parke, J. C. (1979). Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and meningococcus polysaccharides. Lancet, 1, 190–2PubMedCrossRefGoogle Scholar
  138. 138.
    Pandey, J. P., Zollinger, W. D., Fudenberg, H. H. and Loadholt, C. B. (1981). Immunoglobulin allotypes polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med., 297, 686–91Google Scholar
  139. 139.
    Ambrosino, D. M., Schiffman, G., Gotschlich, E. C., Schur, P. H., Rosenberg, G. A., DeLange, G. G., van Loghem, E. and Siber, G. R. (1985). Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J. Clin. Invest., 75, 1935–42PubMedCrossRefGoogle Scholar
  140. 140.
    Siber, G. R., Schur, P. H., Aisenberg, A. C., Weitzman, S. A. and Schiffman, G. (1980). Correlation between serum IgG2 concentrations and the antibody response to bacterial polysaccharide antigens. N. Microbiol., 1, 267–302Google Scholar
  141. 141.
    Ambrosino, D. M., Siber, G. R., Chilmonczyk, B. A, Jernberg, J. B. and Finberg, R. W. (1987). An immunodeficiency characterised by impaired antibody responses to polysaccharides. N. Engl. J. Med., 316, 790–3PubMedCrossRefGoogle Scholar
  142. 142.
    Greenwood, B. M. and Wali, S. S. (1980). Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet, 1, 729–32PubMedCrossRefGoogle Scholar
  143. 143.
    Robbins, J. B. and Schneerson, R. (1987). Haemophilus influenzae type b: the search for a vaccine. Pediatr. Infect. Dis. J., 6, 791–4PubMedCrossRefGoogle Scholar
  144. 144.
    Ward, J. (1987). Newer Haemophilus influenzae type b vaccines and passive prophylaxis. Pediatr. Infect. Dis. J., 6, 799–803PubMedCrossRefGoogle Scholar
  145. 145.
    Beuvery, E. C., Miedema, F., Delft, R. W. van, and Nagel, J., (1982). Meningococcal group C polysaccharide/tetanus toxoid conjugate as immunogen. In Robbins, J. B. et al. (eds), Seminars in Infectious Disease, Bacterial Vaccines, pp. 268–74. (New York: Stratton)Google Scholar
  146. 146.
    Jennings, H. J. and Lugowski, C. (1982). Tetanus toxoid conjugates of the meningococcal polysaccharide. In Robbins, J. B. et al. (eds.), Seminars in Infectious Diseases, Bacterial Vaccines, pp. 247–53. (New York: Stratton)Google Scholar
  147. 147.
    Wyle, F. A., Artenstein, M. S., Brandt, B. L., Tramont, E. C., Kasper, D. L., Altieri, P. L., Berman, S. L. and Lowenthal, J. P. (1972). Immunologic response of man to Group B meningococcal polysaccharide vaccines. J. Infect. Dis., 126, 514–22PubMedCrossRefGoogle Scholar
  148. 148.
    Finne, J., Leinonen, M. and Makela, P. H. (1983). Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet, 2, 355–7PubMedCrossRefGoogle Scholar
  149. 149.
    Lifely, M. R. and Moreno, C. (1986). Vaccine against meningococcal Group B disease. Lancet, 1, 214–15PubMedCrossRefGoogle Scholar
  150. 150.
    Zollinger, W. D, Mandrell, R., Griffiss, J. M. and Altieri, P. (1979). Complex of meningococcal Group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. Invest., 63, 836–48PubMedCrossRefGoogle Scholar
  151. 151.
    Moreno, C., Lifely, M. R. and Esdaile, J. (1985). Effect of aluminium ions on the chemical and immunological properties of Group B polysaccharide. Infect. Immun., 49, 587–92PubMedGoogle Scholar
  152. 152.
    Jennings, H. J., Roy, R. and Gamian, A. (1986). Induction of meningococcal group B polysaccharide specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol., 137, 1708–13PubMedGoogle Scholar
  153. 153.
    Frasch, C. E. and Robbins, J. D. (1978). Protection against Group B meningococcal disease. J. Exp. Med., 147, 629–44PubMedCrossRefGoogle Scholar
  154. 154.
    Craven, D. E. and Frasch, C. E. (1979). Protection against group B meningococcal disease; evaluation of serotype 2 protein vaccines in a mouse bacteremia model. Infect. Immun., 26, 110–17PubMedGoogle Scholar
  155. 155.
    Helting, T. B., Guthohrlein, G., Blackkolb, F. and Ronneberger, H. (1981). Serotype determinant protein of Neisseria meningitidis. Acta. Pathol. Microbiol. Scand., J. Infect. Dis., 2, 201–4Google Scholar
  156. 156.
    Frasch, C. E. and Peppier, M. S. (1982). Protection against Group B meningococcal disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect. Immun., 37, 271–80PubMedGoogle Scholar
  157. 157.
    Zollinger, W. D., Boslego, J. W, Brandt, B., Moran, E. E. and Ray, J. (1986). Safety and antigenicity studies of a polyvalent meningococcal protein-polysaccharide vaccine. Antonie van Leeuwenhoek, 52, 255–8CrossRefGoogle Scholar
  158. 158.
    Beuvery, E. C., Witvliet, M., Timmermans, J. A. M., Poolman, J. T., Hopman, C. T. P., Teerlink, T., Speijers, G. J. A. and Danse, L. H. J. C. (1986). Characteristics of an alternative meningococcal type 15 P1.16 outer membrane protein vaccine. Antonie van Leeuwenhoek, 52, 232–5CrossRefGoogle Scholar
  159. 159.
    Frasch, C. E., Coetzee, G., Zahradnik, J. M. and Wang, L. Y. (1985). New developments in meningococcal vaccines. In Schoolnik, G. K. (ed.), The Pathogenic Neisseria, pp. 633–9. (Washington, DC: American Society for Microbiology)Google Scholar
  160. 160.
    Frasch, C. E., Zahradnik, J. M., Wang, L. Y., Mocca, L. F. and Tsai, C. M. (1988). Antibody response of adults to an aluminium hydroxide-adsorbed Neisseria meningitidis serotype 2b protein group B polysaccharide vaccine. J. Infect. Dis., 158, 710–18PubMedCrossRefGoogle Scholar
  161. 161.
    Wedege, E. and Froholm, L. O. (1986). Human antibody response to a Group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun., 51, 571–8PubMedGoogle Scholar
  162. 162.
    Poolman, J. T. (1988). Meningococcal vaccines. J. Med. Microbiol., 26, 170–2PubMedGoogle Scholar
  163. 163.
    Van Putten, J. M. P., Linders, M. T., Wheel, J. F. L. and Poolman, J. T. (1987). Differential expression of Fe-repressible and growth rate sensitive proteins in Neisseria meningitidis and Neisseria gonorrhoeae. Antonie van Leeuwenhoek, 53, 557–64PubMedCrossRefGoogle Scholar
  164. 164.
    Mietzner, T. A., Luginbuhl, G. H., Sandstrom, E. and Morse, S. A. (1984). Identification of an iron-regulated 37,000 Dalton protein in the cell envelope of Neisseria gonorrhoeae. Infect. Immun., 45, 410–16Google Scholar
  165. 165.
    Keevil, C. W., Davies, D. B., Spillane, B. J. and Mahenthiralingam, E. (1988). Influence of iron-limited and excess continuous culture on the virulence properties of Neisseria gonorrhoeae. In Poolman, J. T. (ed.), Gonococci and Meningococci, pp. 727–9. (Dordrecht: Kluwer)Google Scholar
  166. 166.
    Davies, H. A., Wall, R. A., Borriello, S. P., Patterson, S. and Gaunt, N. (1988). Immunogold electronmicroscopy of the outer membrane proteins of Neisseria meningitidis B.15.P1.16. examined directly from cerebrospinal fluid. J. Med. Microbiol., 27, viGoogle Scholar
  167. 167.
    Cannon, J. G., Black, W. J., Nachamkin, I. and Stewart, P. W. (1984). Monoclonal antibody that recognises an outer membrane antigen common to the pathogenic Neisseria but not to most non pathogenic Neisseria species. Infect. Immun., 43, 994–9PubMedGoogle Scholar
  168. 168.
    Black, J. R., Black, W. J. and Cannon, J. G. (1985). Neisserial antigen H.8 is immunogenic in patients with disseminated gonococcal and meningococcal infections. J. Infect. Dis., 151, 650–7PubMedCrossRefGoogle Scholar
  169. 169.
    Woods, J. P., Aho, E. L., Barritt, D. S., Black, J. R., Connell, T. D., Kawula, T. H., Spinola, S. M. and Cannon, J. G. (1988). The H8 antigen of pathogenic Neisseriae. In Poolman, J. T. (ed.), Gonococci and Meningococci, pp. 613–16. (Dordrecht: Kluwer)Google Scholar
  170. 170.
    Martin, P. M. V., Lavitola, A., Aoun, L., Ancelle, R., Cremieux, A. C. and Riou, J. Y. (1986). A common neisserial antigen evidenced by immunisation of mice with live Neisseria meningitidis. Infect. Immun., 53, 229–33PubMedGoogle Scholar
  171. 171.
    Lavitola, A., Aoun, L., Ohayon, H., Cremieux, A. C., Ancelle, R. and Martin, P. M. V. (1987). The 70 kd neisserial common antigen is a surface exposed antigenically stable peptidic structure. Ann. Inst. Pasteur/Microbiol., 138, 333–42CrossRefGoogle Scholar
  172. 172.
    Aoun, L., Lavitola, A., Aubert, G., Prere, M. F., Cremieux, A. C. and Martin, P. M. V. (1988). Human antibody response to the 70 kd common neisserial antigen in patients and carriers of meningococci or non pathogenic Neisseria. Ann. Inst. Pasteur/Microbiol., 139, 203–12CrossRefGoogle Scholar
  173. 173.
    Brown, M. R. W., Anwar, H. and Lambert, P. A. (1984). Evidence that mucoid Pseudomonas aeruginosa in the cystic fibrosis lung grows under iron-restricted conditions. FEMS Microbiol Lett., 21, 113–17CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • R. A. Wall

There are no affiliations available

Personalised recommendations